ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS MARKET ANALYSIS

Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type (Oral & Parenteral Antibiotics and Topical Antibiotics), By Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025
Code : CMI1531
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Acute Bacterial Skin And Skin Structure Infections Market Size and Trends

Global acute bacterial skin and skin structure infections market is estimated to be valued at USD 4,073.4 Mn in 2025 and is expected to reach USD 6,129.0 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Acute Bacterial Skin And Skin Structure Infections Market Key Factors

To learn more about this report, Request sample copy

There has been increase in prevalence of acute bacterial skin and skin structure infections worldwide due to changing lifestyles and environmental conditions. The market growth is driven by increasing number of surgical procedures that require post-operative infection management. Rising geriatric population prone to such infections further drive the market growth.

Increasing Product Launches by Key Market Players

Market players are involved in launching new drugs, and this is expected to drive growth of the global acute bacterial skin and skin structure infections market over the forecast period. For instance, on July 7, 2021, Melinta Therapeutics, a pharmaceutical company, launched its product- KIMYRSA. KIMYRSA is a lipoglycopeptide antibiotic that provide a complete course of treatment for acute bacterial skin and skin structure infections. KIMYRSA is effective in a single dose of 1200mg injection.